Skip to main content
Erschienen in: Medical Oncology 11/2014

01.11.2014 | Original Paper

Prognostic significance of radical surgical treatment for gastric cancer patients with synchronous liver metastases

verfasst von: Weijia Wang, Han Liang, Hui Zhang, Xuejun Wang, Qiang Xue, Rupeng Zhang

Erschienen in: Medical Oncology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

It has been widely accepted that radical resection is the primary consideration to improve the survival rate for gastric cancer, but it is still controversial whether surgery could bring any substantial survival benefit to gastric cancer patients with synchronous liver metastasis. We retrospectively analyzed pathological and clinical data of 39 gastric patients with liver metastasis who underwent gastric–hepatic radical resection to explore the related prognostic factors. In the whole group of 39 patients, 1-, 2-, 3- and 5-year RFS rates were 30.8, 12.8, 10.3 and 7.7 %; 1-, 2-, 3- and 5-year overall survival (OS) rates were 56.4, 25.6, 17.9 and 10.3 %, respectively. Compared with patients without surgery, operative ones had a statistically significant long-term survival rate. With univariate analysis, lymph node metastasis (N stage), soft tissue invasion and number of liver metastases were significant prognostic factors associated with OS time of synchronous liver metastasis after radical gastrectomy (P < 0.05). What is more, N stage and number of liver metastases were independent factors associated with OS in multivariate analysis. For gastric adenocarcinoma with liver metastases, surgery maybe a superior option if complete resection of gastric and hepatic lesions is feasible and careful postoperative supporting treatment could be received at the same time, especially ones who had less number of liver metastases.
Literatur
1.
Zurück zum Zitat Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17(39):4421–8.PubMedCrossRefPubMedCentral Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17(39):4421–8.PubMedCrossRefPubMedCentral
2.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRef Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRef
3.
Zurück zum Zitat Liu J, Chen L. Current status and progress in gastric cancer with liver metastasis. Chin Med J (Engl). 2011;124(3):445–56.PubMed Liu J, Chen L. Current status and progress in gastric cancer with liver metastasis. Chin Med J (Engl). 2011;124(3):445–56.PubMed
4.
Zurück zum Zitat Schlansky B, Sonnenberg A. Epidemiology of noncardia gastric adenocarcinoma in the United States. Am J Gastroenterol. 2011;106(11):1978–85.PubMedCrossRef Schlansky B, Sonnenberg A. Epidemiology of noncardia gastric adenocarcinoma in the United States. Am J Gastroenterol. 2011;106(11):1978–85.PubMedCrossRef
6.
Zurück zum Zitat Chen J, Tang Z, Dong X, Gao S, Fang H, Wu D, et al. Radiofrequency ablation for liver metastasis from gastric cancer. Eur J Surg Oncol. 2013;39(7):701–6.PubMedCrossRef Chen J, Tang Z, Dong X, Gao S, Fang H, Wu D, et al. Radiofrequency ablation for liver metastasis from gastric cancer. Eur J Surg Oncol. 2013;39(7):701–6.PubMedCrossRef
7.
Zurück zum Zitat Vogl TJ, Gruber-Rouh T, Eichler K, Nour-Eldin NE, Trojan J, Zangos S, et al. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results. Eur J Radiol. 2013;82(2):258–63.PubMedCrossRef Vogl TJ, Gruber-Rouh T, Eichler K, Nour-Eldin NE, Trojan J, Zangos S, et al. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results. Eur J Radiol. 2013;82(2):258–63.PubMedCrossRef
8.
Zurück zum Zitat Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007;7(18):18.PubMedCrossRefPubMedCentral Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007;7(18):18.PubMedCrossRefPubMedCentral
9.
Zurück zum Zitat Kim TO, Kang DH, Kim GH, Heo J, Song GA, Cho M, et al. Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. World J Gastroenterol. 2007;13(6):916–20.PubMedCrossRefPubMedCentral Kim TO, Kang DH, Kim GH, Heo J, Song GA, Cho M, et al. Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. World J Gastroenterol. 2007;13(6):916–20.PubMedCrossRefPubMedCentral
10.
Zurück zum Zitat Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47(3):421–7.PubMedCrossRef Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47(3):421–7.PubMedCrossRef
11.
Zurück zum Zitat Yin Z, Liu C, Chen Y, Bai Y, Shang C, Yin R, et al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): simultaneous or delayed? Hepatology. 2013;57(6):2346–57.PubMedCrossRef Yin Z, Liu C, Chen Y, Bai Y, Shang C, Yin R, et al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): simultaneous or delayed? Hepatology. 2013;57(6):2346–57.PubMedCrossRef
12.
Zurück zum Zitat Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008;19(6):1146–53.PubMedCrossRef Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008;19(6):1146–53.PubMedCrossRef
13.
Zurück zum Zitat Romano F, Garancini M, Uggeri F, Degrate L, Nespoli L, Gianotti L, et al. Surgical treatment of liver metastases of gastric cancer: state of the art. World J Surg Oncol. 2012;10(157):157.PubMedCrossRefPubMedCentral Romano F, Garancini M, Uggeri F, Degrate L, Nespoli L, Gianotti L, et al. Surgical treatment of liver metastases of gastric cancer: state of the art. World J Surg Oncol. 2012;10(157):157.PubMedCrossRefPubMedCentral
14.
Zurück zum Zitat Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg. 2012;397(6):951–7. doi:10.1007/s00423-012-0959-z.PubMedCrossRef Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg. 2012;397(6):951–7. doi:10.​1007/​s00423-012-0959-z.PubMedCrossRef
15.
Zurück zum Zitat Wang YN, Shen KT, Ling JQ, Gao XD, Hou YY, Wang XF, et al. Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases. BMC Surg. 2012;12(20):20.PubMedCrossRefPubMedCentral Wang YN, Shen KT, Ling JQ, Gao XD, Hou YY, Wang XF, et al. Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases. BMC Surg. 2012;12(20):20.PubMedCrossRefPubMedCentral
16.
Zurück zum Zitat Qiu JL, Deng MG, Li W, Zou RH, Li BK, Zheng Y, et al. Hepatic resection for synchronous hepatic metastasis from gastric cancer. Eur J Surg Oncol. 2013;39(7):694–700.PubMedCrossRef Qiu JL, Deng MG, Li W, Zou RH, Li BK, Zheng Y, et al. Hepatic resection for synchronous hepatic metastasis from gastric cancer. Eur J Surg Oncol. 2013;39(7):694–700.PubMedCrossRef
17.
Zurück zum Zitat Takemura N, Saiura A, Koga R, Sano T, Yamaguchi T. Surgical indication and survival benefit of hepatectomy for gastric cancer liver metastasis. Gan To Kagaku Ryoho. 2012;39(13):2455–9.PubMed Takemura N, Saiura A, Koga R, Sano T, Yamaguchi T. Surgical indication and survival benefit of hepatectomy for gastric cancer liver metastasis. Gan To Kagaku Ryoho. 2012;39(13):2455–9.PubMed
19.
Zurück zum Zitat Jagric T, Potrc S. Prediction of liver metastases after gastric cancer resection with the use of learning vector quantization neural networks. Dig Dis Sci. 2010;55(11):3252–61.PubMedCrossRef Jagric T, Potrc S. Prediction of liver metastases after gastric cancer resection with the use of learning vector quantization neural networks. Dig Dis Sci. 2010;55(11):3252–61.PubMedCrossRef
20.
Zurück zum Zitat Dittmar Y, Altendorf-Hofmann A, Rauchfuss F, Gotz M, Scheuerlein H, Jandt K, et al. Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature. Gastric Cancer. 2012;15(2):131–6.PubMedCrossRef Dittmar Y, Altendorf-Hofmann A, Rauchfuss F, Gotz M, Scheuerlein H, Jandt K, et al. Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature. Gastric Cancer. 2012;15(2):131–6.PubMedCrossRef
21.
Zurück zum Zitat Garancini M, Uggeri F, Degrate L, Nespoli L, Gianotti L, Nespoli A, et al. Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile? HPB (Oxf). 2012;14(3):209–15.CrossRef Garancini M, Uggeri F, Degrate L, Nespoli L, Gianotti L, Nespoli A, et al. Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile? HPB (Oxf). 2012;14(3):209–15.CrossRef
22.
Zurück zum Zitat Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13(577):577.PubMedCrossRef Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13(577):577.PubMedCrossRef
23.
Zurück zum Zitat Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol. 2007;37(11):836–42.PubMedCrossRef Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol. 2007;37(11):836–42.PubMedCrossRef
24.
Zurück zum Zitat Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol. 2007;95(7):534–9.PubMedCrossRef Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol. 2007;95(7):534–9.PubMedCrossRef
25.
Zurück zum Zitat Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, et al. Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg. 2009;394(4):647–53.PubMedCrossRef Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, et al. Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg. 2009;394(4):647–53.PubMedCrossRef
26.
Zurück zum Zitat Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et al. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg. 2001;181(2):153–9.PubMedCrossRef Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et al. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg. 2001;181(2):153–9.PubMedCrossRef
27.
Zurück zum Zitat Kumagai K, Shimizu K, Yokoyama N, Aida S, Tanaka T, Yamagata K. Gastrointestinal cancer metastasis and lymphatic advancement. Surg Today. 2010;40(4):301–6.PubMedCrossRef Kumagai K, Shimizu K, Yokoyama N, Aida S, Tanaka T, Yamagata K. Gastrointestinal cancer metastasis and lymphatic advancement. Surg Today. 2010;40(4):301–6.PubMedCrossRef
28.
Zurück zum Zitat Hwang SE, Yang DH, Kim CY. Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. World J Surg. 2009;33(7):1468–72.PubMedCrossRef Hwang SE, Yang DH, Kim CY. Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. World J Surg. 2009;33(7):1468–72.PubMedCrossRef
29.
Zurück zum Zitat Tan MC, Butte JM, Gonen M, Kemeny N, Fong Y, Allen PJ, et al. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. HPB (Oxf). 2013;15(10):803–13.CrossRef Tan MC, Butte JM, Gonen M, Kemeny N, Fong Y, Allen PJ, et al. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. HPB (Oxf). 2013;15(10):803–13.CrossRef
30.
Zurück zum Zitat Liu J, Li JH, Zhai RJ, Wei B, Shao MZ, Chen L. Predictive factors improving survival after gastric and hepatic surgical treatment in gastric cancer patients with synchronous liver metastases. Chin Med J (Engl). 2012;125(2):165–71. Liu J, Li JH, Zhai RJ, Wei B, Shao MZ, Chen L. Predictive factors improving survival after gastric and hepatic surgical treatment in gastric cancer patients with synchronous liver metastases. Chin Med J (Engl). 2012;125(2):165–71.
Metadaten
Titel
Prognostic significance of radical surgical treatment for gastric cancer patients with synchronous liver metastases
verfasst von
Weijia Wang
Han Liang
Hui Zhang
Xuejun Wang
Qiang Xue
Rupeng Zhang
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 11/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0258-3

Weitere Artikel der Ausgabe 11/2014

Medical Oncology 11/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.